FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention relates to a novel sulphonamide compound of formula (I) having inhibiting ribonucleotide reductase activity, and to pharmaceutical compositions containing it as an active ingredient.
[Formula 1]
EFFECT: obtaining novel compounds having ribonucleotide reductase inhibitory activity, which can be used as an antitumour agent, where the tumor is selected from a group, consisting of breast cancer, stomach cancer, lung cancer, pancreatic cancer, Ewing's sarcoma, glioblastoma, liver cancer, mesothelioma, prostate cancer, ovarian cancer, kidney cancer, colon and rectal cancer, melanoma and blood cancer.
31 cl, 4 dwg, 21 tbl, 354 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTITUMOR AGENT | 2018 |
|
RU2770824C2 |
| SULFONAMIDE COMPOUNDS AND THEIR USE | 2018 |
|
RU2781383C2 |
| HETEROAROMATIC MODULATORS OF RETINOL-BOUND ORPHAN GAMMA RECEPTOR | 2017 |
|
RU2771280C2 |
| NOVEL PHENYL PYRROLE DERIVATIVE | 2009 |
|
RU2470917C2 |
| CONDENSED QUINOLINE DERIVATIVE AND USE THEREOF | 2005 |
|
RU2384571C2 |
| 2,4-PYRIMIDINDIAMINE COMPOUNDS HAVING EFFECT IN CASE OF AUTOIMMUNE DISORDERS | 2004 |
|
RU2356901C2 |
| DIAMINE DERIVATIVES | 2003 |
|
RU2333203C2 |
| DERIVATIVES OF HYDROXAMIC OR CARBOXYLIC ACID AND PHARMACEUTICAL OR VETERINARY COMPOSITION ON SAID | 1995 |
|
RU2136657C1 |
| AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
| NONSTEROIDAL MODULATORS OF GLUCOCORTICOID RECEPTORS FOR LOCAL DRUG DELIVERY | 2016 |
|
RU2731618C2 |
